3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Withdrawn
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Carcinoma, Transitional Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Colorectal Neoplasms
1
Chordoma
1
Castration Resistant Prostate Cancer
1
Carcinoma, Merkel Cell
1
Interventions
Rituximab
4
ibrutinib
2
fludarabine phosphate
2
fludarabine
2
blinatumomab
2
Vorinostat
2
Radiation
2
Nivolumab
2
Lenalidomide
2
Gemcitabine
2
Cytarabine
2
Cyclophosphamide
2
CT-P10
2
umbralisib
1
ublituximab
1
tafasitamab
1
polatuzumab vedotin
1
pembrolizumab
1
ofatumumab
1
molibresib
1
magrolimab
1
iberdomide
1
glofitamab
1
entinostat
1
cirmtuzumab
1
carmustine, poliferprosan 20 drug combination
1
asparaginase erwinia chrysanthemi recombinant
1
X-Rays
1
Tacrolimus
1
Stem Cell Transplantation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Lymphoma, B-Cell
×
ALT-803
×
Clear all
NCT07049432
2026-04-01
CARMEN-803
University of Utah
Phase 1
Withdrawn